Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 2019 World Congress on Controversies in Multiple Myeloma (COMy) was held in Paris, France on May 16–18. Experts in the field came together to discuss and debate the latest controversies in the field.

COMy 2019

16–18 May 2019 | Paris, France

COMy 2019

16–18 May 2019 | Paris, France

The 2019 World Congress on Controversies in Multiple Myeloma (COMy) was held in Paris, France on May 16–18. Experts in the field came together to discuss and debate the latest controversies in the field.

Treatment options for relapsed myeloma: assessing the need for auto-SCT 1:11
Treatment options for relapsed myeloma: assessing the need for auto-SCT
Inger Nijhof • 17 May 2019
Second interim analysis of the EMN02 trial 2:44
Second interim analysis of the EMN02 trial
Michele Cavo • 17 May 2019
Supportive care and prophylaxis of the side effects of myeloma drugs 6:41
Supportive care and prophylaxis of the side effects of myeloma drugs
Heinz Ludwig • 17 May 2019
MRD and outcome after transplantation 2:24
MRD and outcome after transplantation
Bruno Paiva • 17 May 2019
Coupling imaging and molecular techniques to determine MRD in MM 1:25
Coupling imaging and molecular techniques to determine MRD in MM
Elena Zamagni • 17 May 2019
Huge potential for CAR-T therapy in myeloma 2:40
Huge potential for CAR-T therapy in myeloma
Andrew Yee • 17 May 2019
Enhancing immune response in multiple myeloma 1:28
Enhancing immune response in multiple myeloma
Sagar Lonial • 17 May 2019
Need for myeloma trials comparing new agents with auto-SCT 2:52
Need for myeloma trials comparing new agents with auto-SCT
Inger Nijhof • 17 May 2019
With new treatment options in myeloma, is auto-SCT still necessary? 1:58
With new treatment options in myeloma, is auto-SCT still necessary?
Inger Nijhof • 17 May 2019
What is the future for myeloma clinical trials? 2:54
What is the future for myeloma clinical trials?
Mohamad Mohty • 17 May 2019
Beyond KarMMa-2: agents targeting BCMA in MM 1:20
Beyond KarMMa-2: agents targeting BCMA in MM
Andrew Yee • 17 May 2019
BCMA-targeting CAR-T: lessons moving forward 1:34
BCMA-targeting CAR-T: lessons moving forward
Sagar Lonial • 17 May 2019
Lenalidomide for smoldering myeloma 2:04
Lenalidomide for smoldering myeloma
Vincent Rajkumar • 17 May 2019
LYRA findings: frontline CyBorD-Dara for myeloma 3:10
LYRA findings: frontline CyBorD-Dara for myeloma
Michael O’Dwyer • 17 May 2019
International Myeloma Workshop (IMW) 2019 1:47
International Myeloma Workshop (IMW) 2019
Kenneth Anderson • 17 May 2019
Proteasome inhibitors-based combinations for elderly MM 2:10
Proteasome inhibitors-based combinations for elderly MM
Maria-Victoria Mateos • 17 May 2019

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals